Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00306787 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes
A Phase 3 study of Genital Herpes, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,179
- Enrollment target
- 20
- Study locations
NCT00306787 is a Phase 3 study of Genital Herpes that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,179 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT00306787, a Phase 3 study of Genital Herpes, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,179 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).
Conditions Studied
Interventions
- DRUG Valacyclovir
- DRUG Famciclovir
- DRUG Placebo matching famciclovir
- DRUG Placebo matching valacyclovir
Study Locations (20)
California
- Providence Clinical Research - Burbank
- Dermatology Research Associates - Los Angeles
- Sacramento Research Medical Group - Sacramento
- North California Research Corp. - Sacramento
- Medical Center for Clinical Research - San Diego
- Conant Research - San Francisco
Florida
- Visions Clinical Research - Boynton Beach
- Women's Medical Research Group, LLC - Clearwater
- International Research Association LLC - Miami
- Orlando Clinical Research Ctr. - Orlando
- Avancia Research - Pembroke Pines
Arizona
- Novartis Investigative Site - Chandler
- Women's Health Research - Phoenix
- Quality of Life Medical & Research Center, LLC - Tucson
Arkansas
- Burke Pharmaceutical Research - Hot Springs
- NEA Women's Clinic - Jonesboro
- The Woman's Clinic - Little Rock
Colorado
- Barbara Davis Center - Denver
- Cohen & Womack, P.C. - Lakewood
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,179 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00306787
The ClinicalTrials.gov registry entry for NCT00306787 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Genital Herpes appearing as the primary indexed condition, and to 4 interventions - of which Valacyclovir is the first listed.
NCT00306787 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00306787 about?
NCT00306787 is a clinical study titled "Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes". This study will assess the safety and efficacy of one-day famciclovir (1000 mg twice a day (b.i.d)) in reducing the duration of genital herpes lesions and the associated symptoms compared to three-day treatment with valacyclovir (500 mg capsule b.i.d).
What is the current status of trial NCT00306787?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,179 participants. The study started on 2006-03. Estimated completion is 2008-02.
What conditions does trial NCT00306787 study?
This clinical trial studies the following conditions: Genital Herpes.
What interventions are being tested in trial NCT00306787?
The interventions under investigation include: Valacyclovir (DRUG), Famciclovir (DRUG), Placebo matching famciclovir (DRUG), Placebo matching valacyclovir (DRUG).
Who is sponsoring clinical trial NCT00306787?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00306787 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genital Herpes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.